While we could not evaluate whether ezrin levels are upregulated in acquired chemotherapeutic drug-resistant breast cancer cell lines in our study, we showed that altering ezrin levels can change the sensitivity of breast cancer cells to DOX and DTX treatment in vitro. The gene discussed is EZR; the disease is breast carcinoma.